title: Beta-phenylethylamine stimulates striatal acetylcholine release through activation of the AMPA glutamatergic pathway.
abstract: Using an in vivo intra-striatal microdialysis technique, we examined the effects of systemically administered beta-phenylethylamine (beta-PEA), a psychomotor stimulating trace amine, on striatal acetylcholine release in freely moving rats. Infusion of N-methyl-D-aspartic acid (NMDA; 10(-5) M) significantly increased acetylcholine release. In addition, locally applied amino-3-hydroxy-5-methylisozasole-4-propionic acid (AMPA; 10(-5) M) significantly increased acetylcholine release in the striatum. Intra-striatal application of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10(-5) M), an AMPA-type glutamatergic receptor antagonist, had little effect on acetylcholine release, while application of MK-801 (10(-5) M, 10(-6) M), an NMDA-type glutamatergic receptor antagonist, significantly reduced acetylcholine release. Acetylcholine within striatal perfusate was significantly increased by intraperitoneal administration of beta-PEA in a dose-dependent manner. This increase in acetylcholine release was completely blocked by application of CNQX (10(-5) M) through the microdialysis probe into the striatum. However, increased acetylcholine response to systemic beta-PEA was unaltered by addition of MK-801 to the perfusion medium. These results suggest a regulatory function of beta-PEA, mediated by AMPA-type glutamatergic receptors, on the release of acetylcholine in the rat striatum.
authors.affiliation: Department of Pharmacotherapeutics, Showa Pharmaceutical University, Tokyo, Japan.
authors.forename: Kota
authors.initials: K
authors.lastname: Ishida
authors.forename: Mikio
authors.initials: M
authors.lastname: Murata
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kato
authors.forename: Iku
authors.initials: I
authors.lastname: Utsunomiya
authors.forename: Keiko
authors.initials: K
authors.lastname: Hoshi
authors.forename: Kyoji
authors.initials: K
authors.lastname: Taguchi
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005971:Glutamates / Q000378:metabolism*; D007274:Injections, Intraperitoneal; D008297:Male; D017551:Microdialysis; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism*; D010627:Phenethylamines / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018091:Receptors, AMPA / Q000819:agonists*; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects; D013268:Stimulation, Chemical
chemical_list: D018691:Excitatory Amino Acid Antagonists; D005971:Glutamates; D010627:Phenethylamines; D018091:Receptors, AMPA; D016194:Receptors, N-Methyl-D-Aspartate; C029261:phenethylamine; D016291:Dizocilpine Maleate; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D000109:Acetylcholine